Nicholas Russo, MD
Vascular Surgery · Neptune City, NJNPI 1679005649
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,693 of the $25,527 with a category attached, or 73.2%. Medtronic accounts for 75.0% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $11,263, 2.2 times the $5,208 reported in 2022.
Across 292 payments — averaging $87.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$19K
- W. L. Gore & Associates, Inc.$4K
- Endologix LLC$574
- Inari Medical, Inc.$428
- Shape Memory Medical Inc.$252
- Lemaitre Vascular, Inc.$190
- plus $1K from 20 others
What the payments were for
- Travel & lodging$5,55922%
- Food & beverage$18,69373%
- Education$1,2755%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 206 | $19,155 |
| W. L. Gore & Associates, Inc. | 33 | $3,737 |
| Endologix LLC | 3 | $574 |
| Inari Medical, Inc. | 6 | $428 |
| Shape Memory Medical Inc. | 3 | $252 |
| Lemaitre Vascular, Inc. | 4 | $190 |
| Silk Road Medical, Inc. | 2 | $148 |
| Cook Medical LLC | 1 | $110 |
| Boston Scientific | 3 | $100 |
| Stryker | 3 | $98 |
| Globus Medical | 2 | $82 |
| Johnson & Johnson(2 entities) | 4 | $76 |
| Artivion, Inc. | 1 | $73 |
| Davol Inc. | 1 | $71 |
| Tactile Systems Technology Inc | 3 | $69 |
| Smith+Nephew | 2 | $67 |
| Angiodynamics, Inc. | 3 | $60 |
| Argon Medical Devices, Inc. | 2 | $44 |
| Acera Surgical, Inc. | 2 | $41 |
| Kerecis Limited | 2 | $37 |
| Cardiva Medical, Inc. | 1 | $27 |
| Imperative Care, Inc | 1 | $24 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Abre$5,944
- NA$4,405
- HawkOne$1,909
- ENDURANT IIS$1,062
- GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis$941
- GORE TAG Conformable Thoracic Endoprosthesis$637
- ENDOCROSS Device$574
- Torus Stent Graft System$574
- IN.PACT AV$438
- Valiant Captivia$423
- GORE VIABAHN Endoprosthesis$375
- GORE EXCLUDER AAA Endoprosthesis$284
- IMPEDE EMBOLIZATION PLUG$233
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$227
- VIABAHN Endoprosthesis with PROPATEN Bioactive Surface$204
- TurboHawk$180
- GORE PROPATEN Vascular Graft$180
- FLOWTRIEVER CATHETER, S$150
- CT THROMBECTOMY SYSTEM KIT$150
- ENROUTE Transcarotid Neuroprotection System$125
How this compares
$25,527 in reported general payments places this provider in the 85th percentile of 182 vascular surgery providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 39 | $33,196 |
| EliquisApixaban | 29 | $27,649 |
| ClopidogrelClopidogrel Bisulfate | 75 | $1,047 |
| Cilostazol | 12 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $76 | $33,19639 claims |
| PfizerEliquis | $17 | $27,64929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 182 vascular surgery providers in New Jersey.
Other vascular surgery in Neptune City
- Matthew SamraNeptune City$16K
- Steven EliasEnglewood$509K
- Michael WildermanHackensack$383K
- David O'ConnorHackensack$272K
- Joseph LombardiPomona$266K
- William BeckermanNew Brunswick$176K
- Neil PoulsenRockaway$148K
- Massimo NapolitanoWayne$147K
- Laurel HastingsCamden$98K
- Danielle PinedaPomona$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.